The First Affilcated Hosipital ,the Air Force Medical University

Xijing Hospital1 site in 1 country10 target enrollmentMay 1, 2022

ConditionsColorectal Cancer

InterventionsSintilimab ，bevcizumab/cetuximab，XELOX

DrugsSintilimab ，bevcizumab/cetuximab，XELOX

Overview

Phase: Not Applicable
Intervention: Sintilimab ，bevcizumab/cetuximab，XELOX
Conditions: Colorectal Cancer
Sponsor: Xijing Hospital
Enrollment: 10
Locations: 1
Primary Endpoint: AE
Status: Recruiting
Last Updated: 3 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

The purpose of this study is to acssess the efficacy and the safety of Sintilimab plus bevacizumab/cetuximab plus XELOX regimen for conversion therapy in patients with advanced colorectal cancer

Registry

clinicaltrials.gov

Start Date

May 1, 2022

End Date

June 30, 2023

Last Updated

3 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

Xijing Hospital

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Patients had to meet all the following conditions to be enrolled in this study:
•Pathological diagnosis of colorectal adenocarcinoma; Ambulatory cases, aged 18-75 years; ECOG score less than or equal to 1; Have not received anti-tumor therapy (such as surgery, radiotherapy, chemotherapy, targeted therapy, immunological therapy);
•Baseline blood routine and biochemical parameters of the subjects met the following criteria:
•Blood routine examination standards shall meet: A. WBC \& GT; 4.0 x 10 / L; b. ANC \> 1.5 x 10 / L; C. the ANC acuity 1.5 x 109 / L; D. HB ≥ 80 g/L; E. PLT acuity 100 x 109 / L;
•Biochemical tests shall meet the following standards:
•A. TBIL 1.5 x ULN or less; B. ALT and AST \& LT; 2.5×ULN, ALT and AST \& LT for patients with liver metastases; 5 x ULN; C. BUN and Cr ≤ 1.5 × ULN or endogenous creatinine clearance ≥ 50 mL/min(Cockcroft-Gault formula).
•No history of other tumors； Be willing and able to follow the protocol during the study； Withdraw from the study at any time during the study without any loss; No history of other tumors; Be willing and able to follow the protocol during the study; Written informed consent was provided prior to study screening and was understood by the patient； Expected life ≥ 6 months

Exclusion Criteria

•Patients were not admitted to the study if they met any of the following criteria:
•Cured basal cell carcinoma of the skin and uterus in patients with other malignancies in the past； Cervical carcinoma in situ is excluded;
•Patients with known positive HER-2 test;
•Pregnant or lactating women are in the reproductive period and have not taken effective contraceptive measures, or have fertility requirements during the study period;
•Serious and uncontrolled medical diseases and infections; Chronic bowel disease or short bowel syndrome;
•Major organ failure, such as compensatory cardiopulmonary, liver and kidney failure; Severe abnormal liver and kidney function metabolism, affecting the normal drug metabolism;
•Patients with investigator-identified propensity for gastrointestinal bleeding and/or abnormal coagulation (INR \& GT; 1.5);
•Active HBV or HCV;
•Patients with peripheral neuropathy NCT-CTCAE ≥ grade 2;
•Patients who were allergic to the drug in the study protocol were not suitable to participate in the clinical study.

Arms & Interventions

experimental

Patients in this group had previously received the following treatment regimens: Oxaliplatin :130 mg/m2, D1, Q3W; Capecitabine :1000mg/m2, bid q2w Sintilimab for injection :200mg, D1, Q3W Bevacizumab :7.5mg/kg, D1, Q3W or cetuximab :500 mg/m, D1, Q2W

Intervention: Sintilimab ，bevcizumab/cetuximab，XELOX